PI
CRNX icon

Putnam Investments’s Crinetics Pharmaceuticals CRNX Stock Holding History

Putnam Investments’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,338
Closed -$427K – 1154
2022
Q4 		$427K Sell
23,338
-13
-0.1% -$229 ﹤0.01% 969
2022
Q3 		$458K Sell
23,351
-423
-2% -$8.63K ﹤0.01% 951
2022
Q2 		$444K Sell
23,774
-1,915
-7% -$38.2K ﹤0.01% 966
2022
Q1 		$564K Sell
25,689
-1,921
-7% -$38.9K ﹤0.01% 969
2021
Q4 		$785K Buy
+27,610
New +$681K ﹤0.01% 890

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Putnam Investments's CRNX Position: Q1 2023 in Review

Putnam Investments sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2023, closing a stake of 23,338 shares — an estimated $427K sold.

Putnam Investments first reported a position in CRNX in Q4 2021 and held it in 5 quarters. The position peaked at $785K in Q4 2021. 128 funds tracked by Wall St. Rank hold CRNX as of Q1 2023.

  • Putnam Investments reported no remaining Crinetics Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Putnam Investments sold 23,338 Crinetics Pharmaceuticals shares in Q1 2023, an estimated $427K.
  • Putnam Investments first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Putnam Investments's Crinetics Pharmaceuticals position peaked at $785K in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2023.

Based on Putnam Investments's 13F filing for Q1 2023, filed 22 May 2023.